TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01495858
Drug: Naproxen Sodium 440 mg (BAYH6689)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received two tablets of Naproxen Sodium 220 mg, single dose, orally.
Study: NCT01495858
Drug: DPH 50 mg
Normalized name: DPH 50 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received two tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
Study: NCT00262964
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to placebo will be treated with one placebo pill per day for eight weeks.
Study: NCT02552342
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04234672
Drug: [14C]TAK-831 IV Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]TAK-831 IV infusion.
Study: NCT04234672
Drug: [14C]TAK-831 Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]TAK-831 oral suspension.
Study: NCT00239811
Drug: FTY720
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04429854
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive.
Study: NCT00190814
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00599664
Drug: OMS201
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMS201 irrigation solution during surgery
Study: NCT02865356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical vehicle solution
Study: NCT00581971
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg bid starting 1 week before radiotherapy and taken through radiotherapy.
Study: NCT04523818
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04523818
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01804777
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiloride 10 mg taken every day for two weeks, along with adherence to specified diet.~On day 14 titrate dose up to Amiloride 20 mg, take every day for two weeks after completion of two week intake of Amiloride 10 mg, along with adherence to specified diet.
Study: NCT02651753
Drug: Lipitor + Lipidil supra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference Drug: Lipitor + Lipidil supra
Study: NCT03668860
Drug: Celestone Soluspan 6Mg/Ml Suspension for Injection
Normalized name: Celestone Soluspan 6mg/ml Suspension for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular. Total dose: 1 mL (6 mg)
Study: NCT01510730
Drug: eradication treatment of Helicobacter pylori infection
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication group receive Omeprazole sodium 20mg, amoxicillin 1g, clarithromycin 500mg orally at the same time twice daily for 7 days.
Study: NCT02549092
Drug: Levodopa-Carbidopa Intestinal Gel
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00501371
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: soft-gel capsule, Qd, 12 weeks
Study: NCT03677622
Drug: Voluven to near maximal stroke volume of the heart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stroke volume guided fluid treatment with Voluven on the basis of restricted fluid therapy
Study: NCT02597101
Drug: AZD9668
Approvals — FDA: no, EMA: no, PMDA: no
Description: study drug
Study: NCT02597101
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for AZD9668 to be added to background drugs
Study: NCT03617263
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
Study: NCT01852435
Drug: R-CEOP-70
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01852435
Drug: R-CEOP-90
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02008565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to the placebo arm will begin the a dose of one capsule per day and will be dose increased or dose decreased using the same algorithm described for the loperamide arm.
Study: NCT00002654
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01190163
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00108914
Drug: GW685698X
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01210170
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo inhalation before albuterol.
Study: NCT02745925
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01853553
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blood pressure medication.
Study: NCT03759522
Drug: DPA-714 PET/MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPA-714 PET/MRI
Study: NCT02155205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT03151057
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03904303
Drug: A 06 ad
Normalized name: tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colonic cleansing before colonoscopy and CT colonografi
Study: NCT00097773
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive placebo, twice daily.
Study: NCT02003547
Drug: AMA0076
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02003547
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01306630
Drug: tivozanib (AV-951) and capecitabine (Xeloda®)
Normalized name: capecitabine Oral Tablet [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivozanib 1.0 mg or 1.5 mg oral once daily for 2 weeks followed by 1 week off. Capecitabine 825 mg/m2, 1000 mg/m2, or 1250 mg/m2, oral twice daily for 2 weeks followed by 1 week off. 1 cycle= 3 weeks. Cycles will be repeated in the absence of disease progression or unacceptable toxicity.
Study: NCT01134848
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml/kg
Study: NCT01134848
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml IM
Study: NCT00968201
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one chewable placebo tablet, once daily at bedtime for 12 weeks
Study: NCT00716534
Drug: Placebo for ABT-869
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator (12.5 mg or 7.5 mg)
Study: NCT00323856
Drug: Alphanate SD/HT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-derived preparation of Factor VIII
Study: NCT00362349
Drug: IgNextGen 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ig NextGen 10% is a liquid formulation and is to be administered intravenously. At the discretion of the Investigator, patients could be administered Ig NextGen 10% in accordance with either of two dosage regimens:~Regimen One: 1 g/kg body weight of Ig NextGen 10% administered daily for two days.~Regimen Two: 0.4 g/kg body weight of Ig NextGen 10% administered daily for five days
Study: NCT00291057
Drug: MALG
Normalized name: Amalgam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 minute application
Study: NCT02879877
Drug: UCB7858
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02879877
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00072566
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01138436
Drug: MEBO Wound Ointment (MEBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application once a day
Study: NCT00389064
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets orally administered in flexible doses of 50 to 300 mg once daily, in the evening for a 9-week treatment period.
Study: NCT01895205
Drug: Red blood cell transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02478957
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo administered via inhalation three times daily for 6 weeks
Study: NCT02325037
Drug: GLPG1837 single ascending doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, oral suspension
Study: NCT01421940
Drug: Placebo drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: After total mesorectal excision for rectal cancer, patients take placebo drug five time per week for 12 weeks.
Study: NCT02372630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo giving orally daily
Study: NCT03882203
Drug: CLAGE-FluBu
Normalized name: INFLUENZA A VIRUS A/VIETNAM/1203/2004 (H5N1, CLADE 1) ANTIGEN (FORMALDEHYDE INACTIVATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladribine combined with cytarabine and VP16 sequential with Fludarabine combined with busulifan
Study: NCT02325037
Drug: Placebo single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, oral suspension matching placebo
Study: NCT02325037
Drug: Placebo multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses, daily for 14 days, oral suspension, matching placebo
Study: NCT05340010
Drug: Human Chorionic Gonadotrophin Intramuscular injection 10.000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: From the 12th to 13th day of the cycle when endometrium reached the optimal thickness ≥8 mm, group 1 (hCG) will receive 10.000 IU hCG intramuscular injection in the morning then vaginal suppository progesterone 400 mg twice a day will be started in the afternoon
Study: NCT01069926
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose oral tablet
Study: NCT00191022
Drug: LY686017
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00191022
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03301285
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment of osteoporosis
Study: NCT00119015
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00416520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
Study: NCT02992938
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00633399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0mg Placebo per day (1-4 tablets per day). Dose increases and dose decreases may occur, but patient will remain at 0mg placebo.
Study: NCT04132011
Drug: Extended Release Opioid Formulation, Shortened Intervals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release opioid, individualized total daily dose, dosing interval is less than every 12 hours
Study: NCT04132011
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose pill manufactured to mimic extended release opioid formulation
Study: NCT04280263
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: caffeine tables containing 150mg caffeine will be provided to patients with instructions to take twice per day
Study: NCT04280263
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo tablets matching the caffeine tablets and will be provided to patients with instructions to take twice per day
Study: NCT02932878
Drug: DSXS topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical treatment
Study: NCT00620022
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
Study: NCT01710657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral Placebo tablets twice daily for 16 weeks.
Study: NCT02187562
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02662712
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to JNJ-56136379 will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
Study: NCT02476799
Drug: IV-PCA containing Fentanyl and Ketorolac
Normalized name: phenylephrine and ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl and 150 mg of ketorolac for 48 hours postoperatively.
Study: NCT00270322
Drug: Marcaine 0.166% + Fentanyl 3.33 mcg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03958422
Drug: cardiomyopeptidin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The main component of cardiomyopeptidin is the peptide active substance extracted from the ventricular myocytes of healthy young pigs.
Study: NCT00437658
Drug: Placebo to DMPA-SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for subcutaneous injection in a pre-filled syringe
Study: NCT00233597
Drug: ferumoxytol or oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02068105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual tablet
Study: NCT03204266
Drug: Arginine recovery supplement
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants take 1 ounce (30mls) of Arginine recovery supplement four times daily 5 days preoperatively and 14 days postoperatively.
Study: NCT03953950
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone Starting dose: 25 mg/day Target dose: 100 mg/day Titration: every 1-2 weeks, based on BP (keep\< 140/90 mmHg, but avoid hypotension \<90/60 mmHg), and serum potassium level (\<5.5 milliequivalent /liter)
Study: NCT01916317
Drug: 0.5% lignocaine 60mM
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00151047
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04209595
Drug: PLX038
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I: Dose escalation will follow the classical 3+3 trial design by Fibonacci sequence. Phase II: Maximum tolerated dose (MTD) identified in phase I. PLX038 (PEGylated SN38) will be administered as a 1 hour (-10 minutes / +30 minutes) intravenous (IV) infusion on Day 1 of each cycle (21 days).
Study: NCT03824314
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml fentanyl (25 μg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
Study: NCT01480752
Drug: Lornoxicam
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDL injection of 0/2 ml of lornoxicam (4mg/ml),before the root therapy and after the inferior alveolar injection
Study: NCT00804570
Drug: LY2196044
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
Study: NCT00804570
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily, orally, 16 weeks
Study: NCT00487136
Drug: warfarin plus ABT-335 plus rosuvastatin 5 mg
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.
Study: NCT00487136
Drug: warfarin plus ABT-335 plus rosuvastatin 20 mg
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.
Study: NCT01480752
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDl injection of 0/2 ml normal saline before the root therapy and after inferior alveolar injection
Study: NCT01166100
Drug: Fluoxetine Hydrochloride
Normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine Hydrocloride Delayed Release Capsules, 90 mg of Dr. Reddy's Laboratories.
Study: NCT02254174
Drug: Serevent® Diskus®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02254174
Drug: Spiriva®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01520909
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with no active pharmaceutical ingredient
Study: NCT02226185
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: supplement of placebo two times per day for 2-3 years
Study: NCT04377711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo Inhaler
Study: NCT03378323
Drug: Multiple injection local anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple injection local anesthetic
Study: NCT02792426
Drug: Nicorette Inhalator
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00830206
Drug: Zithromax®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Suspension
Study: NCT03378323
Drug: Single injection local anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection local anesthetic
Study: NCT00615472
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
Study: NCT02715336
Drug: Ovulation induction with hCG and Lupron (GnRH agonist)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients treated for infertility are categorized as a low-, normal- or high responder according to their estimated ovarian response to hormonal stimulation. This classification dictates the hormonal stimulation regimen that they will receive. In contrast to hCG triggering, GnRHa triggering is characterized by simultaneous LH and FSH surges, similar to natural ovulation. A combination of GnRHa plus hCG for triggering creates simultaneous LH and FSH surges by the GnRHa, which resembles physiologic ovulation triggering, together with sustained LH-like activity from the hCG, stimulating the corpus luteum to excrete sufficient hormonal endometrial support.
Study: NCT01019603
Drug: Tazaroc Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tazarotene gel applied daily for 22 days.
Study: NCT03824119
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard postpartum care (including administration of NSAIDs)
Study: NCT02096913
Drug: Dolormin® extra (Ibuprofen)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 4 weeks (Arm I; n=6).~In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the treatment period.
Study: NCT03116659
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 100 mg PO BID x 14 days
Study: NCT02607683
Drug: XAF5 (concentration A: 0.1%)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02607683
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02867176
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The ketorolac group (Dolac, Siegfried Rhein, Mexico) was instructed to take their 10-mg tablets every 8 hours on the day of surgery and for the first 3 postoperative days.
Study: NCT02096913
Drug: Dolormin® extra (Ibuprofen)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 12 weeks (Arm II, n=6).~In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the first 4 weeks of treatment and may be reduced to 20mg/d during the following treatment period after individual risk-benefit assessment.
Study: NCT01276730
Drug: Interferon, Retinoic Acid and radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-α2b will be administered 3 times a week for four weeks at a dose of 3 x 106 IU subcutaneously concomitant with radiotherapy. The first dose will be administered on the day the subject starts radiotherapy; 13-cis-retinoic acid will be administered orally at a dose of 40 mg/day for 1 month starting from day 1 of radiotherapy; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions to both the study group and the control group. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
Study: NCT02211937
Drug: BI 44847 solution, low dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02211937
Drug: BI 44847 suspension, high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02211937
Drug: BI 44847 tablet, low dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02211937
Drug: BI 44847 tablet, high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00993070
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle gel, applied 4 times per day for 8 weeks
Study: NCT01389102
Drug: Estradiol transdermal one 90 μL spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator